HemaSphere

SJR Rank #1,450H-index: 42SJR: 2.001Best quartile: Q1Open AccessAPC: US$2,480Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

John Wiley and Sons Inc

Country

United States

Type

journal

SJR by Edition

2022202500.551.11.652.2

Subject Categories

  • HematologyQ1

Areas: Medicine

Most published research topics

Acute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentMultiple Myeloma Research and TreatmentsMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsCAR-T cell therapy researchHemoglobinopathies and Related DisordersAcute Lymphoblastic Leukemia researchHematopoietic Stem Cell Transplantation

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0150300450600

Documents per Year

20222025055110165220

Detailed Information

ISSN

2572-9241

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

3.52

References per Document

35.47

Coverage

2017-2026

Scope

HemaSphere publishes results of highly relevant basic, translational, and clinical research in hematology. We are especially looking for strong studies reporting novel findings that are of high impact to the field of hematology. Review articles, guideline articles, and controversy articles provide clear overviews and discussions of new developments as well as recommendations for patient care. HemaSphere is the premier hematology information resource, which is covered by the HemaTopics section in the journal. This section provides insightful discussions on all aspects related to hematology, including summaries of important articles, reports of new therapies, discussions on European policy, and other hematology news items. HemaSphere is an open access journal, powered by the European Hematology Association, and dedicated to supporting hematology patient care, research, and education worldwide.

Metrics from SCImago Journal Rank 2025. View on SCImago